Drug Profile
Research programme: KRAS inhibitors - Mirati Therapeutics
Alternative Names: G12D inhibitor; KRAS inhibitor programme - Mirati TherapeuticsLatest Information Update: 25 Jan 2024
Price :
$50
*
At a glance
- Originator Array BioPharma; Mirati Therapeutics
- Developer Mirati Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action KRAS protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Colorectal cancer; Non-small cell lung cancer; Pancreatic cancer
Most Recent Events
- 23 Jan 2024 Mirati Therapeutics has been acquired by Bristol-Myers Squibb
- 16 Feb 2023 Preclinical development in Colorectal cancer in is ongoing USA (PO) (Mirati therapeutics pipeline, February 2023)
- 16 Feb 2023 Preclinical development in Non-small cell lung cancer in is ongoing USA (PO) (Mirati therapeutics pipeline, February 2023)